During this observational study, the investigators aim to assess the ability of ICU clinicians to predict the risk of impending organ failure and retrospectively compare it to the performance of previously published machine learning models. The central hypothesis of this study is that the treating physician can predict impending organ failure in adult ICU patients with similar accuracy as the best previously publishes machine learning models.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* patient minimum age of 18 years
* emergency admission to the ICU
* arterial line in place
Exclusion Criteria:
* documented refusal (on the general consent form) to participate to clinical research
* patients with neurologic conditions that impair the patient's level of consciousness (including, but not limited to stroke, traumatic brain injury, intracranial hemorrhage, CNS infections; except polytrauma)
* patients on mechanical circulatory support systems (IABP, VA-ECMO, Impella, VAD) or extracorporeal membrane oxygenation (VV-ECMO) at any time during their ICU stay;
* patients receiving end-of-life care or are admitted for the sole purpose of evaluating organ donation
Primary outcome measure(s)
Clinician prediction of circulatory failure within 8 hours compared to published ML models — Assessments are collected within the first 72 hours following admission. This outcome compares the area under the receiver operating characteristic curve (auROC) for two methods of predicting circulatory failure within 8 hours of each assessment time point: (1) ICU clinicians' risk estimates, and (2) previously published machine learning (ML) models applied retrospectively. For each assessment, we compute the auROC separately for clinicians and for the ML model for the same time points and patients. The difference in auROC (clinician minus ML) is the main measure of interest, evaluated under a non-inferiority framework with a margin of 0.025.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
